Accordingly, these results suggest that although RPL22L1 promotes malignant progression of GBM through EGFR/STAT3 activation, the TMZ resistance caused by RPL22L1 is mainly result in the inhibition of apoptosis induced by STAT3 activation (Fig. 6D). Here, EGFR is linked to glioblastoma.